camrelizumab + chidamide + S-1

This combination therapy consists of **camrelizumab**, a humanized monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor; **chidamide** (tucidinostat), an orally active, subtype-selective histone deacetylase (HDAC) inhibitor; and **S-1**, an oral fluoropyrimidine-based chemotherapy containing tegafur, gimeracil, and oteracil. The regimen is primarily being investigated by the First Affiliated Hospital of Soochow University for the treatment of advanced biliary tract cancer (BTC) in patients who have failed first-line therapy. Camrelizumab functions as a checkpoint inhibitor to reactivate T-cell-mediated anti-tumor immunity. Chidamide acts as an epigenetic modulator, potentially enhancing the immunogenicity of tumor cells and reversing resistance to immunotherapy. S-1 provides cytotoxic effects by inhibiting thymidylate synthase and DNA synthesis. This triplet combination aims to leverage synergistic effects between immunotherapy, epigenetic modulation, and chemotherapy to improve outcomes in refractory BTC.

Other names

Camrelizumab plus Chidamide plus S-1